Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and the Therapeutic Effectiveness of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

NCT02503501 is registered in ClinicalTrials.gov with HealthPartners Institute as lead sponsor.

NCT NCT02503501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02503501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and the Therapeutic Effectiveness of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
Lead sponsor
HealthPartners Institute
Phase
Phase 2
Overall status
Terminated
Start date
September 28, 2015
Completion date
February 15, 2019
Enrollment
49 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease (ad), mild cognitive impairment